Regeneron Pharmaceuticals Analyst Price Targets

Regeneron Pharmaceuticals Inc

REGNNASDAQ

Trade with Public

$750.22

10.641.44%

마지막 업데이트: Oct 9, 10:28 AM

$738.07

-1.50-0.2%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

17Buy

5Hold

Consensus RatingBuy# Analysts22Avg. Consensus PT$814Upside to Avg. PT+8.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$737→$810
Oct 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$772→$780
Oct 7, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$758→$779
Oct 6, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$900→$950
Oct 1, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$870→$930
Oct 1, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$850
Sep 29, 2026	RBC Capital	Brian Abrahams	Maintained	Sector Perform	$737
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Buy	$800→$920
Aug 17, 2026	Leerink Partners	David Risinger	PT Raise	Market Perform	$641→$824
Aug 3, 2026	Citigroup	Geoff Meacham	PT Raise	Neutral	$700→$740
Aug 3, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$1000→$1030
Jul 31, 2026	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$696→$737
Jul 31, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$730→$758
Jul 31, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$750→$795
Jul 31, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$700→$750
Jul 31, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$769→$772
Jul 21, 2026	Guggenheim	Brad Canino	PT Raise	Buy	$995→$1000
Jul 9, 2026	Piper Sandler	Biren Amin	PT Cut	Overweight	$855→$854
Jul 8, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$788→$730
Jul 7, 2026	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$707→$696

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $737 to $810.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

Truist Securities analyst Gregory Renza maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $772 to $780.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $758 to $779.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

JP Morgan analyst Chris Schott maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $900 to $950.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.

Benzinga Newsdesk

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Analysts upgraded BJRI, UTHR, OXY, BP and REGN, raising ratings and/or price targets.

Avi Kapoor

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

뉴스

파트너 / 기고자

벤징가 글로벌

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PROJP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PROJefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

뉴스

파트너 / 기고자

벤징가 글로벌

Regeneron Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PROJP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PROJefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $810

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $780

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $779

PRO
JP Morgan Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $950

PRO
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930